Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -35.63% | -51.22% | -55.93% | -52.24% | -43.05% |
| Total Depreciation and Amortization | 23.16% | 27.47% | 39.68% | 63.08% | 95.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.35% | 40.39% | 35.58% | 33.92% | 36.69% |
| Change in Net Operating Assets | -115.70% | -145.37% | -34.66% | -138.07% | -130.10% |
| Cash from Operations | -38.99% | -55.83% | -64.18% | -74.34% | -68.56% |
| Capital Expenditure | 55.62% | -42.44% | -49.90% | -68.88% | 10.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 99.74% | 101.96% | 131.47% | -260.28% | -72.21% |
| Cash from Investing | 99.27% | 101.14% | 130.25% | -254.30% | -70.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -31.50% | -31.54% | -96.06% | 11.03% | -23.12% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.68% | -124.94% | -- | 105.73% | 98.57% |
| Cash from Financing | -31.54% | -31.89% | -96.00% | 15.00% | -19.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.51% | 106.40% | -177.99% | -218.28% | -194.60% |